NmVac4-A/C/Y/W-135: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== NmVac4-A/C/Y/W-135 == | |||
[[File:Meningococcal_meningitis_A,C,Y,W-135_Vaccine.png|thumb|NmVac4-A/C/Y/W-135 vaccine]] | |||
NmVac4-A/C/Y/W-135 | |||
'''NmVac4-A/C/Y/W-135''' is a quadrivalent [[meningococcal vaccine]] designed to protect against four serogroups of the bacterium ''[[Neisseria meningitidis]]'': A, C, Y, and W-135. These serogroups are responsible for causing [[meningococcal disease]], which can lead to serious conditions such as [[meningitis]] and [[septicemia]]. | |||
NmVac4-A/C/Y/W-135 is | |||
== | == Composition and Mechanism == | ||
NmVac4-A/C/Y/W-135 is a [[conjugate vaccine]], which means it contains polysaccharides from the bacterial capsule of each serogroup conjugated to a protein carrier. This conjugation enhances the immune response, particularly in young children, by inducing a T-cell dependent response. The vaccine stimulates the production of [[antibodies]] that target the polysaccharide capsules of the meningococcal bacteria, thereby preventing infection. | |||
== | == Indications == | ||
The vaccine is indicated for use in individuals from the age of 9 months and older. It is particularly recommended for adolescents, travelers to regions where meningococcal disease is endemic, and individuals with certain medical conditions that increase their risk of infection, such as those with a damaged or removed [[spleen]] or [[complement deficiency]]. | |||
== | == Administration == | ||
* [[Meningococcal | |||
NmVac4-A/C/Y/W-135 is administered via [[intramuscular injection]]. The vaccination schedule may vary depending on the age of the recipient and the specific guidelines of the country. Typically, a single dose is sufficient for adolescents and adults, while younger children may require additional doses. | |||
== Efficacy == | |||
The vaccine has been shown to be highly effective in preventing disease caused by the A, C, Y, and W-135 serogroups. It significantly reduces the incidence of meningococcal disease in vaccinated populations and contributes to [[herd immunity]], thereby protecting unvaccinated individuals as well. | |||
== Safety == | |||
[[File:MenA.jpg|thumb|NmVac4-A/C/Y/W-135 vaccine serogroup A]] | |||
[[File:MenC.jpg|thumb|NmVac4-A/C/Y/W-135 vaccine serogroup C]] | |||
NmVac4-A/C/Y/W-135 is generally well-tolerated. Common side effects include mild pain and redness at the injection site, fever, and fatigue. Serious adverse reactions are rare. The vaccine is contraindicated in individuals with a known hypersensitivity to any component of the vaccine. | |||
== Global Impact == | |||
The introduction of NmVac4-A/C/Y/W-135 has had a significant impact on the control of meningococcal disease worldwide. It is part of routine immunization programs in many countries and is also used in outbreak control strategies. The vaccine has contributed to a substantial decline in the incidence of disease caused by the covered serogroups. | |||
== Related Pages == | |||
* [[Meningococcal disease]] | |||
* [[Neisseria meningitidis]] | * [[Neisseria meningitidis]] | ||
* [[ | * [[Vaccination]] | ||
* [[ | * [[Conjugate vaccine]] | ||
[[File:MenY.jpg|thumb|NmVac4-A/C/Y/W-135 vaccine serogroup Y]] | |||
[[File:MenW135.jpg|thumb|NmVac4-A/C/Y/W-135 vaccine serogroup W-135]] | |||
[[Category:Vaccines]] | [[Category:Vaccines]] | ||
[[Category:Meningococcal vaccines]] | [[Category:Meningococcal vaccines]] | ||
Latest revision as of 11:01, 23 March 2025
NmVac4-A/C/Y/W-135[edit]
NmVac4-A/C/Y/W-135 is a quadrivalent meningococcal vaccine designed to protect against four serogroups of the bacterium Neisseria meningitidis: A, C, Y, and W-135. These serogroups are responsible for causing meningococcal disease, which can lead to serious conditions such as meningitis and septicemia.
Composition and Mechanism[edit]
NmVac4-A/C/Y/W-135 is a conjugate vaccine, which means it contains polysaccharides from the bacterial capsule of each serogroup conjugated to a protein carrier. This conjugation enhances the immune response, particularly in young children, by inducing a T-cell dependent response. The vaccine stimulates the production of antibodies that target the polysaccharide capsules of the meningococcal bacteria, thereby preventing infection.
Indications[edit]
The vaccine is indicated for use in individuals from the age of 9 months and older. It is particularly recommended for adolescents, travelers to regions where meningococcal disease is endemic, and individuals with certain medical conditions that increase their risk of infection, such as those with a damaged or removed spleen or complement deficiency.
Administration[edit]
NmVac4-A/C/Y/W-135 is administered via intramuscular injection. The vaccination schedule may vary depending on the age of the recipient and the specific guidelines of the country. Typically, a single dose is sufficient for adolescents and adults, while younger children may require additional doses.
Efficacy[edit]
The vaccine has been shown to be highly effective in preventing disease caused by the A, C, Y, and W-135 serogroups. It significantly reduces the incidence of meningococcal disease in vaccinated populations and contributes to herd immunity, thereby protecting unvaccinated individuals as well.
Safety[edit]
NmVac4-A/C/Y/W-135 is generally well-tolerated. Common side effects include mild pain and redness at the injection site, fever, and fatigue. Serious adverse reactions are rare. The vaccine is contraindicated in individuals with a known hypersensitivity to any component of the vaccine.
Global Impact[edit]
The introduction of NmVac4-A/C/Y/W-135 has had a significant impact on the control of meningococcal disease worldwide. It is part of routine immunization programs in many countries and is also used in outbreak control strategies. The vaccine has contributed to a substantial decline in the incidence of disease caused by the covered serogroups.
Related Pages[edit]
